Vol 9: Preclinical Therapeutic Potential of a Nitrosylating Agent in the Treatment of Ovarian Cancer.Reportar como inadecuado



 Vol 9: Preclinical Therapeutic Potential of a Nitrosylating Agent in the Treatment of Ovarian Cancer.


Vol 9: Preclinical Therapeutic Potential of a Nitrosylating Agent in the Treatment of Ovarian Cancer. - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Descargar gratis o leer online en formato PDF el libro: Vol 9: Preclinical Therapeutic Potential of a Nitrosylating Agent in the Treatment of Ovarian Cancer.
This article is from PLoS ONE, volume 9.AbstractThis study examines the role of s-nitrosylation in the growth of ovarian cancer using cell culture based and in vivo approaches. Using the nitrosylating agent, S-nitrosoglutathione GSNO, a physiological nitric oxide molecule, we show that GSNO treatment inhibited proliferation of chemoresponsive and chemoresistant ovarian cancer cell lines A2780, C200, SKVO3, ID8, OVCAR3, OVCAR4, OVCAR5, OVCAR7, OVCAR8, OVCAR10, PE01 and PE04 in a dose dependent manner. GSNO treatment abrogated growth factor HB-EGF induced signal transduction including phosphorylation of Akt, p42-44 and STAT3, which are known to play critical roles in ovarian cancer growth and progression. To examine the therapeutic potential of GSNO in vivo, nude mice bearing intra-peritoneal xenografts of human A2780 ovarian carcinoma cell line 2×106 were orally administered GSNO at the dose of 1 mg-kg body weight. Daily oral administration of GSNO significantly attenuated tumor mass p



Autor: Giri, Shailendra; Rattan, Ramandeep; Deshpande, Mandar; Maguire, Jacie L.; Johnson, Zachary; Graham, Rondell P.; Shridhar, Viji

Fuente: https://archive.org/







Documentos relacionados